Annual EBITDA
-$94.89 M
-$5.56 M-6.22%
December 31, 2023
Summary
- As of February 12, 2025, XFOR annual EBITDA is -$94.89 million, with the most recent change of -$5.56 million (-6.22%) on December 31, 2023.
- During the last 3 years, XFOR annual EBITDA has fallen by -$35.95 million (-60.99%).
- XFOR annual EBITDA is now -667.93% below its all-time high of -$12.36 million, reached on December 31, 2015.
Performance
XFOR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$34.00 M
-$127.22 M-136.47%
September 30, 2024
Summary
- As of February 12, 2025, XFOR quarterly EBITDA is -$34.00 million, with the most recent change of -$127.22 million (-136.47%) on September 30, 2024.
- Over the past year, XFOR quarterly EBITDA has dropped by -$127.22 million (-136.47%).
- XFOR quarterly EBITDA is now -136.47% below its all-time high of $93.22 million, reached on June 30, 2024.
Performance
XFOR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$7.74 M
-$33.46 M-130.09%
September 30, 2024
Summary
- As of February 12, 2025, XFOR TTM EBITDA is -$7.74 million, with the most recent change of -$33.46 million (-130.09%) on September 30, 2024.
- Over the past year, XFOR TTM EBITDA has dropped by -$33.46 million (-130.09%).
- XFOR TTM EBITDA is now -130.09% below its all-time high of $25.72 million, reached on June 30, 2024.
Performance
XFOR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XFOR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.2% | -136.5% | -130.1% |
| 3 y3 years | -61.0% | -136.5% | -130.1% |
| 5 y5 years | -192.3% | -100.0% | +84.7% |
XFOR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.3% | at low | -136.5% | +37.5% | -130.1% | +93.8% |
| 5 y | 5-year | -87.7% | at low | -136.5% | +37.5% | -130.1% | +93.8% |
| alltime | all time | -667.9% | at low | -136.5% | +37.5% | -130.1% | +93.8% |
X4 Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$34.00 M(-136.5%) | -$7.74 M(-130.1%) |
| Jun 2024 | - | $93.22 M(-287.1%) | $25.72 M(-121.1%) |
| Mar 2024 | - | -$49.81 M(+190.5%) | -$121.92 M(+28.5%) |
| Dec 2023 | -$94.89 M(+6.2%) | -$17.15 M(+3069.9%) | -$94.89 M(-10.1%) |
| Sep 2023 | - | -$541.00 K(-99.0%) | -$105.57 M(-15.9%) |
| Jun 2023 | - | -$54.42 M(+138.9%) | -$125.48 M(+37.6%) |
| Mar 2023 | - | -$22.78 M(-18.1%) | -$91.22 M(+2.1%) |
| Dec 2022 | -$89.33 M(+5.7%) | -$27.82 M(+36.0%) | -$89.33 M(-1.5%) |
| Sep 2022 | - | -$20.46 M(+1.5%) | -$90.66 M(+1.5%) |
| Jun 2022 | - | -$20.16 M(-3.5%) | -$89.32 M(+1.8%) |
| Mar 2022 | - | -$20.90 M(-28.3%) | -$87.76 M(+3.8%) |
| Dec 2021 | -$84.54 M(+43.4%) | -$29.15 M(+52.4%) | -$84.54 M(+15.9%) |
| Sep 2021 | - | -$19.12 M(+2.8%) | -$72.97 M(+3.6%) |
| Jun 2021 | - | -$18.60 M(+5.2%) | -$70.45 M(+6.4%) |
| Mar 2021 | - | -$17.67 M(+0.5%) | -$66.25 M(+12.4%) |
| Dec 2020 | -$58.94 M | -$17.58 M(+5.8%) | -$58.94 M(+14.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$16.61 M(+15.4%) | -$51.62 M(-0.8%) |
| Jun 2020 | - | -$14.39 M(+38.8%) | -$52.02 M(+3.1%) |
| Mar 2020 | - | -$10.37 M(+1.1%) | -$50.47 M(-0.2%) |
| Dec 2019 | -$50.56 M(+55.7%) | -$10.26 M(-39.7%) | -$50.56 M(+26.4%) |
| Sep 2019 | - | -$17.00 M(+32.3%) | -$39.99 M(+19.0%) |
| Jun 2019 | - | -$12.85 M(+22.9%) | -$33.59 M(+3.1%) |
| Mar 2019 | - | -$10.45 M(-3439.9%) | -$32.58 M(+0.4%) |
| Dec 2018 | -$32.46 M(+2.7%) | $313.00 K(-103.0%) | -$32.44 M(-25.6%) |
| Sep 2018 | - | -$10.61 M(-10.4%) | -$43.62 M(-1.4%) |
| Jun 2018 | - | -$11.84 M(+14.7%) | -$44.22 M(+17.6%) |
| Mar 2018 | - | -$10.32 M(-5.1%) | -$37.60 M(+19.0%) |
| Dec 2017 | -$31.60 M(+56.6%) | -$10.87 M(-3.0%) | -$31.60 M(+25.3%) |
| Sep 2017 | - | -$11.21 M(+114.9%) | -$25.21 M(+80.0%) |
| Jun 2017 | - | -$5.21 M(+20.7%) | -$14.01 M(+59.3%) |
| Mar 2017 | - | -$4.32 M(-3.6%) | -$8.80 M(+96.4%) |
| Dec 2016 | -$20.18 M(+63.3%) | -$4.48 M | -$4.48 M |
| Dec 2015 | -$12.36 M | - | - |
FAQ
- What is X4 Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals annual EBITDA year-on-year change?
- What is X4 Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals quarterly EBITDA year-on-year change?
- What is X4 Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals TTM EBITDA year-on-year change?
What is X4 Pharmaceuticals annual EBITDA?
The current annual EBITDA of XFOR is -$94.89 M
What is the all time high annual EBITDA for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high annual EBITDA is -$12.36 M
What is X4 Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, XFOR annual EBITDA has changed by -$5.56 M (-6.22%)
What is X4 Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of XFOR is -$34.00 M
What is the all time high quarterly EBITDA for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high quarterly EBITDA is $93.22 M
What is X4 Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, XFOR quarterly EBITDA has changed by -$127.22 M (-136.47%)
What is X4 Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of XFOR is -$7.74 M
What is the all time high TTM EBITDA for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high TTM EBITDA is $25.72 M
What is X4 Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, XFOR TTM EBITDA has changed by -$33.46 M (-130.09%)